What is the appropriate workup for suspected Factor V Leiden thrombophilia?

Factor V Leiden Workup

Test for Factor V Leiden only in targeted clinical scenarios where results will directly influence treatment decisions—not as routine screening—using direct DNA-based genotyping as the preferred method. 1

Testing Methodology

Use direct DNA-based genotyping as the primary testing approach. If a functional assay (activated Protein C resistance) is performed and positive, confirm with DNA testing to distinguish heterozygotes from homozygotes. 2

Critical caveat: Patients on heparin or with lupus anticoagulant should proceed directly to molecular testing, as these conditions interfere with functional assays. 2

When to Test: Recommended Indications

The 2025 ACMG guidelines provide the most current framework. Testing is recommended when:

High-Priority Scenarios

• VTE at unusual sites (cerebral, splanchnic, hepatic, mesenteric veins) 1
• VTE provoked by pregnancy or postpartum 1
• VTE associated with oral contraceptive use 1
• VTE with positive family history of thrombophilia in first- or second-degree relatives OR first-degree relative with VTE at young age 1
• Age <50 with any venous thrombosis 2
• Recurrent VTE 1
• Low activated Protein C resistance on functional testing 1

Consider Testing In:

• VTE age >50 (except when active malignancy present) 2
• Asymptomatic siblings of homozygous Factor V Leiden or double heterozygotes (FVL + prothrombin G20210A) 1
• Asymptomatic pregnant women or those contemplating pregnancy/estrogen use who have a first-degree relative with VTE and known homozygous FVL or double heterozygosity 1
• Women with recurrent pregnancy loss, severe preeclampsia, placental abruption, intrauterine growth retardation, or stillbirth 2
• Myocardial infarction in female smokers under age 50 2

When NOT to Test

Do not test in these situations:

• General population screening 1, 2
• Routine screening before oral contraceptive use in asymptomatic women without personal/family VTE history 2
• Arterial thrombotic disorders (coronary artery disease, stroke) as routine practice—the association is not established 1
• Active malignancy with VTE 2
• Patients >60 without family history of thrombosis or previous thrombotic event (though some evidence suggests testing may still be valuable) 2
• MTHFR variant testing—explicitly not recommended as part of thrombophilia workup 1

Timing Considerations

Critical timing issue: Avoid testing during acute thrombosis when possible, as anticoagulation and acute phase reactants can affect results. However, DNA-based testing for Factor V Leiden is not affected by anticoagulation, unlike functional protein C/S/antithrombin assays. 3

If testing reveals Factor V Leiden, also test for prothrombin G20210A mutation as these can be multiplexed and identifying double heterozygotes is clinically important for risk stratification. 2

Family Testing Algorithm

Test asymptomatic relatives only when:

• A family member is confirmed homozygous for Factor V Leiden 1
• First-degree relatives of individuals with VTE diagnosed before age 50 2
• Results will influence clinical decisions (pregnancy planning, contraceptive choice, surgical prophylaxis counseling) 1

Use direct DNA testing for family members, not functional assays. 2

Common Pitfalls to Avoid

1. Ordering indiscriminate thrombophilia panels: Only 5.8% of requests in one recent study met guideline criteria 4
2. Testing during acute thrombosis: 32% of tests in one cohort were inappropriately timed 4
3. Failing to confirm positive functional assays with DNA testing 2
4. Testing for MTHFR: No clinical utility for thrombophilia workup 1
5. Screening low-risk populations: Generates low-value results and diagnostic uncertainty 4

Clinical Context

The rationale for selective testing is that Factor V Leiden results should change management—influencing duration of anticoagulation, pregnancy thromboprophylaxis decisions, or counseling about avoidable risks (extended travel, immobilization, hormone use). 1 Homozygotes and double heterozygotes are classified as "high-risk thrombophilia" and warrant more aggressive prevention strategies. 1

Testing has limited utility when results won't alter treatment, which is why routine screening after a first provoked VTE in older patients with clear precipitants (surgery, malignancy) is not recommended. 1